Purpose: Chronic bronchitis (CB), a chronic obstructive pulmonary disease (COPD) phenotype defined by persistent mucus hypersecretion and cough, is associated with poor quality of life, exacerbations, and lung function impairment. Bronchial Rheoplasty (BR) delivers non-thermal pulsed electric fields to airway epithelium and submucosa. Preliminary studies demonstrated reduced airway goblet cell hyperplasia and symptom improvement in response to BR. This study aimed to further assess the safety and clinical feasibility of BR in the setting of CB.
Patients And Methods: This 3-center, single-arm study evaluated the safety and feasibility of BR in Canadian patients. The major inclusion criteria were the sum of CAT first 2 questions (cough and mucus) ≥ 7 out of 10 and FEV ≥ 30% predicted. Right-sided airways were treated first; left, 1 month later. Serious adverse events (SAEs) were tabulated through 12 months. Outcomes were evaluated using the SGRQ and CAT.
Results: Ten patients with CB were enrolled and followed for 12 months. The BR procedure was successful in all patients (mean age 69 ± 5.8 years, post-BD FEV 77.1 ± 28.3, SGRQ 56.2 ± 8.8, CAT 25.4 ± 4.7). Only one SAE, a COPD exacerbation 13 days following the BR procedure, was considered device related. No additional SAEs occurred through 12 months, and 90% of the patients were CAT responders (≥ 2-point improvement) at 3 and 6 months. Similar results were observed in SGRQ.
Conclusion: BR was safe and well-tolerated. Meaningful symptom improvement was observed through 12 months, suggesting BR may be a viable treatment option for patients with CB.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268598 | PMC |
| http://dx.doi.org/10.2147/COPD.S464506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A quantitative method for assessing treatment-related changes within the airway mucosa in patients with chronic bronchitis.
Respir Med
January 2025
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, Philadelphia, PA, 19140, USA. Electronic address:
Background: No standardized method has yet been established for evaluating airway mucosal aberrancies associated with chronic obstructive pulmonary disease (COPD) or chronic bronchitis (CB). While goblet cell hyperplasia (GCH) is an established pathognomonic hallmark of the CB disease process, no standardized method exists for acquiring mucosal biopsies and assessing morphologic airway mucosa alterations. Additionally, the impacts from interventions targeting the airway mucosa are not well defined.
View Article and Find Full Text PDFInterventional pulmonology for chronic inflammatory airway diseases.
Chin Med J Pulm Crit Care Med
September 2024
Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg 69126, Germany.
Article Synopsis
- - Chronic inflammatory airway diseases like chronic bronchitis, COPD, emphysema, and asthma are significant healthcare issues that can be addressed with interventional treatments alongside standard medical therapy.
- - These minimally invasive procedures, such as bronchial thermoplasty and lung volume reduction techniques, directly target the airways to relieve symptoms and improve lung function by reducing hyperinflation and mucus production.
- - The review provides insights into various interventional methods based on specific disease types, helping pulmonologists choose the best treatment options for their patients.
The Use of Bronchial Rheoplasty in Emphysema Patients Previously Treated with Endoscopic Lung Volume Reduction: A Case Series.
Int J Chron Obstruct Pulmon Dis
August 2024
Department of Cardiology, Section for Lung Transplantation and Respiratory Medicine, Rigshospitalet Heart Center, Copenhagen, Denmark.
Endoscopic lung volume reduction (ELVR) is an established treatment option for patients with severe emphysema. Not all patients are candidates for this type of intervention, and in the context of significant airway secretions, they may be excluded from treatment. Bronchial Rheoplasty (BR) was developed to treat mucus hypersecretion by delivering nonthermal pulsed electric fields to the airway epithelium and submucosa.
View Article and Find Full Text PDFBronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOx.
Int J Chron Obstruct Pulmon Dis
July 2024
Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Purpose: Chronic bronchitis (CB), a chronic obstructive pulmonary disease (COPD) phenotype defined by persistent mucus hypersecretion and cough, is associated with poor quality of life, exacerbations, and lung function impairment. Bronchial Rheoplasty (BR) delivers non-thermal pulsed electric fields to airway epithelium and submucosa. Preliminary studies demonstrated reduced airway goblet cell hyperplasia and symptom improvement in response to BR.
View Article and Find Full Text PDFDeveloping Interventions for Chronic Obstructive Pulmonary Disease.
Semin Respir Crit Care Med
October 2024
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Albany Medical College, Albany, New York.
Chronic obstructive pulmonary disease (COPD) is an incurable, progressive respiratory disease that may have a significant negative impact on the morbidity and mortality of affected patients. A substantial portion of the world's population is affected by COPD, and despite optimal medical management with medications, supplemental oxygen, and pulmonary rehabilitation, many patients are left debilitated because of this disease. Bronchoscopic treatment modalities offer a less-invasive method for the treatment of refractory COPD compared to surgical interventions and have expanded the potential therapeutic options for these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!